Introduction {#section5-1758835919833864}
============

Breast cancer, one of the three most common malignancies worldwide, is a disease strongly related with age, with the highest incidence among elderly, postmenopausal women.^[@bibr1-1758835919833864]^ Approximately 70--80% of breast cancers are estrogen receptor (ER) or progesterone receptor (PgR)-positive and thus potentially sensitive to endocrine therapy (ET). The main international guidelines endorse ET as the preferred first-line option for hormone receptor-positive (HR+) disease in postmenopausal women, even in the presence of visceral disease (but not in cases of visceral crisis or concern/proof of endocrine resistance). At some point of her clinical history, every woman with HR+/HER2 metastatic breast cancer (MBC) will receive one or more ET lines in the context of a sequential strategy.^[@bibr2-1758835919833864]^ The choice of the upfront and subsequent agents mainly depends on the type of adjuvant ET as well as the disease-free interval from its completion; these can be aromatase inhibitors (AIs), tamoxifen, or fulvestrant.^[@bibr3-1758835919833864]^ However, almost all women with initially endocrine-sensitive disease will develop a resistance to ET, either as an early failure (*de novo* resistance), or as a progression after an initial response (acquired resistance).^[@bibr4-1758835919833864]^ The optimal sequence of single endocrine agents and combinations with targeted agents is yet to be defined and is a research priority.

Fulvestrant (Faslodex®) is an anti-estrogen that belongs to the selective ER down-regulators class and is characterized by a novel mechanism of action, being a pure antagonist of ER, without partial agonist activity.^[@bibr5-1758835919833864]^ Preclinical and clinical studies have also demonstrated the lack of cross-resistance between fulvestrant and other hormonal treatments.^[@bibr6-1758835919833864],[@bibr7-1758835919833864]^

According to the suggested concept of the dose-dependent activity of fulvestrant,^[@bibr8-1758835919833864]^ the phase III study CONFIRM randomized patients with MBC, progressing after previous endocrine treatment with tamoxifen or AIs, to receive fulvestrant 500 mg (F500) *versus* 250 mg (F250). F500 significantly improved progression-free-survival (PFS) compared with F250 as well as the overall response rate (ORR) and clinical benefit rate (CBR)^[@bibr9-1758835919833864]^; this study led to the adoption of F500 for the treatment of HR+ postmenopausal women with disease progression following anti-estrogen therapy. An unplanned survival analysis showed that F500 had a favorable hazard ratio 0.81 (*p* = 0.016) compared with F250 in terms of the risk of death, with an absolute 4.1 month increase in median overall survival (OS).^[@bibr10-1758835919833864]^

The phase II trial FIRST randomized women with previously untreated disease to receive F500 *versus* anastrozole. As for the primary endpoint of CBR, F500 and anastrozole proved to be similar, as well as for ORR^[@bibr11-1758835919833864],[@bibr12-1758835919833864]^; notably, the median time to progression and OS significantly favored F500.^[@bibr13-1758835919833864]^ Finally, the phase III study FALCON confirmed the superiority of F500 over anastrozole as first-line therapy for HR+ untreated metastatic disease.^[@bibr14-1758835919833864]^

The recently published randomized, phase III, placebo-controlled, PALOMA-3 trial demonstrated that the addition of the cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib to F500, in women relapsed or progressed after prior ET, was able to provide a significant benefit in PFS and also improved quality of life (QoL).^[@bibr15-1758835919833864],[@bibr16-1758835919833864]^

Beside randomized clinical trials, so far, few data are available regarding the effectiveness and safety of F500 in the real-life setting. The aim of this observational, prospective, longitudinal cohort study was to describe the patterns of treatment and performance of F500 in a large population of unselected women with MBC, with a focus on the potential prognostic or predictive factors for disease outcome and treatment response.

Patients and methods {#section6-1758835919833864}
====================

Study design {#section7-1758835919833864}
------------

This is an open-label, longitudinal, prospective, multicenter cohort study conducted from January 2011 to December 2015 at three oncology institutions in Northern Italy (two university hospitals, one community hospital). All of them usually treat more than 150 new cases of breast cancer per year and are representative of the geographical area. The study was approved by the Ethical Committee of the Coordinator Center (ICS Maugeri IRCCS), protocol no. 2086 CE; all patients provided written informed consent for the inclusion in the study, analysis, and anonymized publication of clinical data.

Study population {#section8-1758835919833864}
----------------

Eligible patients were postmenopausal women with MBC and histologically proven HR+ disease (defined as ER or PgR \>1% by immunohistochemistry \[IHC\]), and candidates to receive F500 following anti-estrogen therapy, either in the adjuvant or metastatic setting, according to their contingent clinical situation. Additional inclusion criteria were HER2 negative (HER2−) disease (immunohistochemistry 0--1 or IHC 2, confirmed as fluorescent *in situ* hybridization (FISH) negative), measurable or evaluable lesions according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, version 1.1,^[@bibr17-1758835919833864]^ and a life expectancy of at least 4 months. They were also required to have adequate bone marrow, hepatic, renal function, according to clinical practice guidelines for antineoplastic drug administration; no prespecified limits were set for blood tests in order to have the closest situation to clinical practice. Previous chemotherapy (CT) or ET for metastatic disease was allowed. Data collection started from the administration of the first dose of F500 and included the patients' performance status and age at study entry, disease characteristics, HR and HER2 status, sites and number of metastases, and tumor biology, as well as previous therapies received in the adjuvant and metastatic setting.

Treatment plan {#section9-1758835919833864}
--------------

Treatment was administered until documented progressive disease (PD), unacceptable toxicity, or patient refusal and was given in an outpatient setting, according to the officially approved national guidelines (500 mg i.m. on days 0, 14, 28; every 4 weeks thereafter). The tumor assessment was performed approximately every 4 months, unless there were clinical signs of PD, according to clinical practice and the physician's approach, as well as to the sites of metastatic disease. A complete blood count and organ function test was performed before each cycle; no prespecified dose delays or modifications were planned.

Statistical analysis {#section10-1758835919833864}
--------------------

The primary aim of the study was to analyze the effectiveness of F500 in terms of PFS and CBR. PFS was defined as the time interval from the start of therapy with F500 to the date of PD; CBR was defined as the percentage of patients experiencing a complete response (CR), partial response (PR), or stable disease (SD) lasting 6 months or more. Clinical responses were evaluated according to the RECIST criteria, version 1.1.

Secondary aims included the evaluation of safety events and OS. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria (NCI-CTCAE), version 4.^[@bibr18-1758835919833864]^ OS was calculated as the interval from therapy start with F500 to the date of death or of last follow-up evaluation. A subgroup analysis was performed to identify potential prognostic or predictive factors for disease outcome and treatment response. Population characteristics and treatment-related variables were analyzed using standard descriptive statistical methods. The Chi-squared test was applied to categorical variables. The level of significance of statistical tests was set at *p* \< 0.05. PFS and OS were estimated using the Kaplan--Meier method. The Cox regression model was used for univariate and multivariate analysis.

As for subgroup analysis, the variables investigated were: age (\>65 *versus* ⩽65 years); tumor stage at disease presentation (IV *versus* I--III); disease-free interval (DFI) from adjuvant treatment (\>24 months *versus* ⩽24 months); number of metastatic sites (\>2 *versus* ⩽2); liver involvement (yes *versus* no); prior CT before F500 (yes *versus* no); line of treatment with F500 (⩾3 *versus* 1--2); and treatment setting (treatment at PD *versus* maintenance).

Results {#section11-1758835919833864}
=======

Patient characteristics {#section12-1758835919833864}
-----------------------

A total of 490 patients met the research criteria and 480 were considered for data analysis. Overall, 10 patients were excluded for incomplete or missing data, while all women were evaluable for toxicity, as described in the patient flow diagram ([Figure 1](#fig1-1758835919833864){ref-type="fig"}). Clinical and demographic characteristics are reported in [Table 1](#table1-1758835919833864){ref-type="table"}. The median age at study entry was 66 years (range 56--81); 39.2% of the patients were aged 65 years or less. Eastern Cooperative Oncology Group (ECOG) performance status was 0--1 in almost all patients (91.6%). As for patients with metachronous disease progression (79% of the evaluable population), the median DFI was 64 months (range 18--196). About 30% of these patients had received an AI, with or without tamoxifen, in the adjuvant setting. As for the metastatic setting, 24% of patients had received F500 as a first-line option, while 41% had received CT alone or in sequence with a hormonal agent (an AI in 95% of cases). A total of 101 patients had a metastatic disease *ab initio* (21% of the overall population).

![Patient flow chart.](10.1177_1758835919833864-fig1){#fig1-1758835919833864}

###### 

Patient characteristics.

![](10.1177_1758835919833864-table1)

                                                 Number         \%
  ---------------------------------------------- -------------- ----------
  **Enrolled/evaluable**                         **490/480**    **97.9**
  Median age, years (range)                      66 (56--81)    
   ⩽65 years                                     188            39.2
   \>65 years                                    292            60.8
  ECOG performance status                                       
   0                                             245            51
   1                                             195            40.6
   2                                             40             8.3
  Receptor status                                               
   ER+/PgR+                                      306            63.7
   ER+/PgR−                                      99             20.6
   ER−/PgR+                                      48             10
   ICH HER2-neu+ (FISH negative)                 27             5.6
  Prior adjuvant therapy                                        
   tamoxifen                                     148            30.8
   aromatase inhibitors                          90             18.7
   tamoxifen ⩾ aromatase inhibitors              55             11.4
   chemotherapy + hormone therapy                86             17.9
  Median DFI, months (range)                     64 (18--196)   
   ⩽24 months                                    56             22.1
   \>24 months                                   323            77.9
  Prior therapy for metastatic disease                          
   None                                          115            23.9
   hormone therapy                               168            35
   chemotherapy                                  138            28.7
   Chemotherapy + hormone therapy                59             12.2
  Prior hormone therapy for metastatic disease                  
   anastrozole                                   113            49.7
   letrozole                                     47             20.7
   exemestane                                    52             22.9
   tamoxifen                                     15             6.6
  *De novo* metastatic disease                   101            21
  Dominant metastatic sites                                     
   Bone                                          270            56.2
   Liver                                         96             20
   Lung                                          60             12.5
   nodes/soft tissues/skin                       54             11.2
  Number of metastatic sites                                    
   1                                             302            62.9
   2                                             109            22.7
   ⩾3                                            69             14.3

DFI, disease-free interval; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescent *in situ* hybridization; ICH HER2-neu, immunohistochemistry HER2-neu; PgR, progesterone receptor.

The majority of patients had metastases involving one or two organs (62.9% and 22.7% respectively). In addition, 32.5% of patients had visceral involvement, whereas 56.2% had bone-only metastases. A total of 306 patients received F500 after PD, 102 and 72 were treated as maintenance therapy following first or second-line CT, respectively ([Figure 2](#fig2-1758835919833864){ref-type="fig"}). As shown in [Figure 3](#fig3-1758835919833864){ref-type="fig"}, treatment patterns of F500 interestingly changed over the study period, with an increasing proportion of women receiving the drug as an always earlier line of therapy and as a maintenance strategy.

![Patterns of treatment with F500 in the whole population.\
CT: chemotherapy; F500, fulvestrant 500 mg; PD: progressive disease; SD: stable disease.](10.1177_1758835919833864-fig2){#fig2-1758835919833864}

![Patterns of treatment with F500 across the study period.\
(a) The increasing proportion of patients receiving F500 in the first and second line of treatment across the study period (compared with those treated in subsequent lines).\
(b) The increasing proportion of patients receiving F500 as a maintenance strategy across the study period (compared with those treated at disease progression).\
F500, fulvestrant 500 mg.](10.1177_1758835919833864-fig3){#fig3-1758835919833864}

Treatment activity {#section13-1758835919833864}
------------------

A minimum of 6 cycles of F500 was administered to all patients, with a median number of 14 (range 6--28). According to the treatment setting, patients who received F500 after PD had an ORR of 17.6%, with a CR of 3.4%. Disease stabilization was achieved in 122 patients, lasting more than 24 weeks in 74 of them (36.0%), for an overall CBR of 53.6% (95% CI 0.46--0.60). A total of 47 patients (22.9%) experienced PD during F500 treatment. Within the population receiving the drug for *de novo* metastatic disease, an ORR of 47.5% was observed, with 44.6% of PR and 24.8% of SD ⩾24 weeks, for an overall CBR of 72.3%. As for the women treated with F500 as a maintenance strategy, a slight difference was observed between those treated following disease stabilization or response in terms of both ORR (4.5% and 8.3%, respectively) and CBR (43.9% and 56.5% respectively). The median time to response was 6 months (range 4--9).

At a median follow up of 35 months (range 18--56), no difference in median PFS was observed in patients receiving the drug at PD or as a maintenance (11.6 and 11.1 months, respectively). When analyzed according to the treatment line (1st, 2nd, ⩾3rd) median PFS values were significantly prolonged when F500 was administrated as a first-line treatment (12.5 months), to decrease progressively in second and subsequent lines of treatment (11.4 and 6.2 months respectively). By contrast, in the maintenance setting, similar PFS values were observed among subgroups of patients treated at disease stabilization or following a response (11.2 and 10.9, respectively; [Table 2](#table2-1758835919833864){ref-type="table"}). Median OS in the whole population was 26.8 months, ranging from 32.4 months in the first line to 22.0 and 13.7 months in second and subsequent lines, respectively ([Figure 4](#fig4-1758835919833864){ref-type="fig"}).

###### 

Treatment activity in the whole population (480 evaluable patients).

![](10.1177_1758835919833864-table2)

  F500 after PD                                  F500 as maintenance                                                                                             
  ---------------------------------------------- --------------------- ----------- -------------------------------- ------------------------- ----------- ------ -------------
  *Overall response rate*                        36                    17.6        0.13--0.23                       *Overall response rate*   9           8.3    0.04--0.15
   Complete response                             7                     3.4         0.01--0.06                        Complete response        1           0.9    0.002--0.05
   Partial response                              29                    14.1        0.10--0.19                        Partial response         8           7.4    0.03--0.13
   SD ⩾ 24 weeks                                 74                    36.0        0.29--0.42                        SD ⩾ 24 weeks            52          48.1   0.39--0.57
   SD \< 24 weeks                                48                    23.4        0.18--0.29                        SD \< 24 weeks           18          16.7   0.10--0.24
   PD                                            47                    22.9        0.17--0.29                        PD                       29          26.9   0.19--0.35
  *Clinical benefit rate*                        110                   53.6        0.46--0.60                       *Clinical benefit rate*   61          56.5   0.47--0.65
  ***De novo* metastatic disease (*n* = 101)**                                                                      **After SD (*n* = 66)**                      
  *Overall response rate*                        48                    47.5        0.38--0.57                       *Overall response rate*                      
   Complete response                             3                     3.0         0.01--0.08                        Complete response        --          --     --
   Partial response                              45                    44.6        035--0.54                         Partial response         3           4.5    0.01--0.12
   SD ⩾ 24 weeks                                 25                    24.8        0.17--0.34                        SD ⩾ 24 weeks            26          39.4   0.28--0.51
   SD \< 24 weeks                                8                     7.9         0.04--0.14                        SD \< 24 weeks           10          15.2   0.08--0.25
   PD                                            12                    11.9        0.06--0.19                        PD                       17          25.8   0.16--0.37
  *Clinical benefit rate*                        73                    72.3        0.62--0.80                       *Clinical benefit rate*   29          43.9   0.32--0.55
  **Progression-free survival, months**                                                                                                                          
                                                 Median                Range                                        Median                    Range              
  **F500 after PD**                                                                                                 **F500 as maintenance**                      
  Overall population (*n* = 306)                 11.6                  8.1--16.2   Overall population (*n* = 174)   11.1                      8.3--14.8          
   First line                                    12.5                  10.216.2     After OR                        10.9                      9.1--13.6          
   Second line                                   11.4                  8.8--12.2    After SD                        11.2                      7.4--12.2          
   ⩾3 lines                                      6.2                   4.8--9.2                                                                                  

CI, confidence interval; F500, fulvestrant 500 mg; OR, objective response; PD, progressive disease; SD, stable disease.

![The median OS in the whole population according to treatment line: (a) first line; (b) second line; (c) subsequent lines.](10.1177_1758835919833864-fig4){#fig4-1758835919833864}

A subgroup analysis was performed in order to identify variables of potential predictive or prognostic value. Both the presence of liver metastasis and the treatment line were significantly associated with a worse PFS at the univariate analysis, and the difference was maintained in the multivariate analysis. For OS, the presence of liver metastasis, previous CT for metastatic disease and the F500 treatment line were negatively associated with a worse OS, but only the presence of liver metastasis maintained its negative predictive role also in multivariate analysis ([Table 3](#table3-1758835919833864){ref-type="table"} and [Figure 5](#fig5-1758835919833864){ref-type="fig"}).

###### 

Univariate and multivariate analysis for progression-free survival and overall survival.

![](10.1177_1758835919833864-table3)

                                                          **Progression-free survival**   **Overall survival**                                                                                       
  ------------------------------------------------------- ------------------------------- ---------------------- ------------------- ----------- ------------------- ----------- ------------------- -----------
  **Variables**                                           HR (95% CI)                     *p* value              HR (95% CI)         *p* value   HR (95% CI)         *p* value   HR (95% CI)         *p* value
  Age (\>65 *versus* ⩽65 years)                           0.89 (0.68--1.15)               0.371                  0.98 (0.74--1.29)   0.873       1.35 (0.83--2.2)    0.229       2 (0.96--3.43)      0.072
  Stage (IV *versus* ⩽ III)                               0.93 (0.64--1.34)               0.695                  1.26 (0.81--1.97)   0.308       0.94 (0.48--1.83)   0.851       0.79 (0.34--1.81)   0.577
  Number of metastatic sites (\>2 *versus* ⩽2)            1.29 (0.95--1.76)               0.102                  1.01 (0.72--1.43)   0.933       1.82 (1.09--3.02)   0.021       1.03 (0.59--1.82)   0.913
  Liver metastases (yes *versus* no)                      2.23 (1.65--3.01)               \<0.001                2.16 (1.54--3.04)   \<0.001     4.30 (2.70--6.84)   \< 0.001    4.11 (2.36--7.14)   \<0.001
  Chemotherapy for metastatic disease (yes *versus* no)   1.48 (1.14--1.93)               0.004                  0.93 (0.65--1.32)   0.667       2.56 (1.47--4.47)   0.001       1.28 (0.59--2.76)   0.537
  F500 treatment line (⩾3 *versus* 1--2)                  2.11 (1.52--2.93)               \< 0.001               2.04 (1.36--3.05)   0.001       2.68 (1.54--4.68)   0.001       2.04 (1--4.17)      0.051
  F500 treatment setting (at PD *versus* maintenance)     0.75 (0.54--1.21)               0.503                  0.87 (0.64--1.31)   0.723       1.25 (0.73--2.24)   0.462       1.51 (0.83--1.97)   0.236

CI, confidence interval; F500, fulvestrant 500 mg; HR, hazard ratio; PD, progressive disease.

![Median overall survival according to visceral involvement: (a) patients with liver metastasis; (b) patients without liver metastasis.](10.1177_1758835919833864-fig5){#fig5-1758835919833864}

Treatment safety {#section14-1758835919833864}
----------------

The median drug exposure was 14.6 months (range 5.6--26.1). Overall, treatment was well tolerated with good compliance in the outpatient setting. No severe drug-related adverse events were recorded; in no case was treatment delayed or interrupted and no death occurred because of toxicity. As expected, the most common adverse events were joint disorders, hot flushes, and myalgia. No substantial difference in incidence and severity of adverse events was seen between the two groups of women receiving the drug at progression of disease or as maintenance therapy ([Table 4](#table4-1758835919833864){ref-type="table"}).

###### 

Treatment-related adverse events (480 evaluable patients).

![](10.1177_1758835919833864-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------
                                        F500 at progression disease (n=306)   F500 as maintenance (n=174)                                       
  ------------------------------------- ------------------------------------- ----------------------------- ----- -------- ----- --------- ---- --------
  Non-hematological\                    \                                     \                             \     \        \     \         \    \
  Joint disorders\                      31\                                   (10.1)\                       10\   (3.2)\   19\   (10.9)\   4\   (2.2)\
  Hot flushes\                          20\                                   (6.5)\                        12\   (3.9)\   10\   (5.7)\    8\   (4.5)\
  Myalgia\                              14\                                   (4.5)\                        8\    (2.6)\   9\    (5.1)\    2\   (1.1)\
  Fatigue\                              12\                                   (3.9)\                        4\    (6.2)\   10\   (5.7)\    -\   -\
  Nausea\                               8\                                    (2.6)\                        2\    (0.6)\   6\    (3.4)\    3\   (1.7)\
  Back pain\                            9\                                    (2.9)\                        4\    (1.3)\   2\    (1.1)\    3\   (1.7)\
  Dyspnoea\                             7\                                    (2.2)\                        6\    (1.9)\   3\    (1.7)\    1\   (0.5)\
  Hypertension\                         11\                                   (3.5)\                        8\    (2.6)\   8\    (4.5)\    5\   (2.8)\
  Injection site reactions\             13\                                   (4.2)\                        10\   (3.2)\   5\    (2.8)\    6\   (3.4)\
  Weight gain\                          5                                     (1.6)                         -     -        2     (1.1)     -    -
  Peripheral oedema                                                                                                                             

  Hematological                                                                                                                                 

  Anemia                                3                                     (0.9)                         \-    \-       2     (1.1)     \-   \-

  Leucopenia                            2                                     (0.6)                                        2     (1.1)          \-

  Alanine aminotransferase increase     5                                     (1.6)                         \-    \-                       \-   \-

  Aspartate aminotransferase increase   4                                     (1.3)                         \-    \-       3     (1.7)     \-   \-
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#section15-1758835919833864}
==========

The aim of this study was to verify the performance of F500 in a real-world setting, while analyzing the patterns of treatment and the physicians' actual prescription attitude. To the best of the authors' knowledge, the experience reported here is the largest real-life series of unselected patients treated with F500 over a 5-year time span. In such a heterogeneous cohort we can identify at least three different clinical situations. The first scenario involves women receiving the drug at disease progression after prior adjuvant or first-line treatment (*n* = 205). In this population, a median PFS of 11.6 months and a CBR of 54% were observed. These results compare favorably with the values of 45.6% CBR and median PFS of 6.5 months reported by the phase III CONFIRM trial, in which the most represented subgroup consisted of patients relapsed on adjuvant ET or presenting with *de novo* advanced disease progressing on the first line.^[@bibr9-1758835919833864],[@bibr10-1758835919833864]^ By contrast, in our population, 139 (68%) out of 205 patients received F500 beyond the third line and up to the seventh line of treatment; in addition, 64% of them had previously been treated with CT alone or in sequence with different endocrine agents.

A second picture emerges with regards to women receiving the drug as a first-line treatment option: our data mainly refer to patients with *de novo* metastatic disease, who are recognized as having relatively good prognosis when compared with those with recurring disease.^[@bibr19-1758835919833864],[@bibr20-1758835919833864]^ The observed median PFS of 12.5 months with a CBR of 72.2% are in keeping with those of the FALCON trial, which reported a median PFS of 16.6 months in ET-naïve patients diagnosed with MBC from less than 1 year, and among which only one-third had previously received CT.^[@bibr14-1758835919833864]^ Although the results of the FALCON study suggest a particular sensitivity to F500 in *de novo* stage IV disease, caution should be used when interpreting these results, because this study was not powered to assess this question. We agree with the hypothesis that metastatic disease with visceral involvement indicates not only a more aggressive behavior, but also a larger tumor burden and heterogeneous estrogen sensitivity.^[@bibr21-1758835919833864]^ In this special population, a combination of F500 with other endocrine or target agents might be appropriate.^[@bibr16-1758835919833864],[@bibr22-1758835919833864]^ On the other hand, a recently reported prespecified subgroup analysis across the PALOMA-3 population showed that the presence of visceral metastases maintained an independent negative prognostic value, also when F500 was combined with palbociclib.^[@bibr16-1758835919833864]^

Of interest in our study, is the analysis of patients with liver metastasis: a poorer outcome in terms of both PFS and OS was observed at statistical analysis, with liver involvement resulting in the only one negative prognostic factor for disease outcome at multivariate analysis. These findings address the still open question on the potential higher benefit achievable with endocrine single agents in women without visceral metastases, for which ET is widely considered to be the best therapeutic strategy.^[@bibr23-1758835919833864][@bibr24-1758835919833864][@bibr25-1758835919833864]--[@bibr26-1758835919833864]^

An additional, an element of heterogeneity in our experience regards the third and last clinical situation, concerning the use of F500 as a maintenance strategy. In daily clinical practice, switching to ET during CT is a commonly employed strategy, aiming to reduce treatment side effects without compromising the disease outcome. Such an approach is based on the biological rationale of the control of the regrowth of hormone-dependent clones after maximum cytoreduction obtained by CT^[@bibr27-1758835919833864]^ and is also supported by the European Consensus Guidelines with a level of evidence of 1C.^[@bibr2-1758835919833864]^ In our series, 36% of enrolled women received the drug as a maintenance ET following first- or second-line CT (102 and 72 patients, respectively): the observed median PFS was similar to that of patients treated at PD (11.1 and 11.6 months, respectively), while a slight difference between patients treated following disease stabilization or documented response was observed in terms of both ORR (4.5% and 8.3%, respectively) and CBR (43.9% and 56.5%, respectively). Data on this topic are scarce in the literature, and only one prospective randomized study with maintenance medroxyprogesterone is available.^[@bibr28-1758835919833864]^ The results of a large retrospective study on 934 MBC patients receiving ET after response or stabilization following first-line CT compare favorably with ours, because this strategy seemed related to a better PFS and OS. As in our population, the achieved benefit appeared of the same magnitude in patients achieving OR or SD.^[@bibr29-1758835919833864]^ Such an approach reflects the modern continuum of MBC management, aiming towards stable and prolonged disease control instead of an objective and measurable response throughout an appropriate agent sequencing.

Our findings add information to interpreting patterns of treatment with F500 in a large unselected population of women with HR+/HER2− MBC, within the limits of an uncontrolled study of an observational nature, lacking in comparator and QoL data. As is known, the strength of real-life experiences is based on the possibility to verify the reproducibility of evidence-based data in daily clinical practice. The available real-world experiences, although not fully comparable for population heterogeneity, treatment line, and clinical context, globally confirm that F500 is an effective and well-tolerated therapy for postmenopausal HR+/HER2− MBC.^[@bibr30-1758835919833864][@bibr31-1758835919833864][@bibr32-1758835919833864][@bibr33-1758835919833864]--[@bibr34-1758835919833864]^ The most recently reported study described a CBR of 61% on 160 patients treated with F500 in different lines, with a PFS of 7 months and an OS of 35 months; as in our experience, visceral involvement had a prognostic value for PFS, whereas endocrine sensitivity and upfront metastatic disease negatively correlated with OS. As expected, patients who had received previous first-line ET for advanced disease exhibited a worse outcome and a lower CBR, while patients with lower body mass index had a PFS advantage.^[@bibr35-1758835919833864],[@bibr36-1758835919833864]^ In our experience, the use of F500 in early disease phases translated into a better PFS and OS, with a statistically significant impact on OS at multivariate analysis. Interestingly, a progressive shift of the physician's attitude to prescribe F500 as an always earlier treatment line was observed across the study period, somehow preceding the subsequent evidence-based data.

The increasing number of options for ET and ET-based therapies is challenging the traditional approach to agent sequencing for HR+ MBC. In this complex scenario, the best agent prioritization as well as the patient selection, from both a biological and clinical point of view, remain at least partially undefined, because of the lack of *ad hoc* designed randomized clinical trials and reliable molecular biomarkers, particularly to effectively identify endocrine sensitivity.^[@bibr37-1758835919833864],[@bibr38-1758835919833864]^

At present, the critical issue is: which patient can be treated with a single drug, and which one requires a combination treatment? The hard question remains unanswered, because an impact on OS is still unproven for the combination regimen, and the clinical criteria currently adopted to patient selection are clearly inadequate.^[@bibr39-1758835919833864]^

In this view, strategies to overcome resistance are of increasing interest, as recently reported in the TREND study, suggesting the addition of a CDK inhibitor at progression on ET has the potential to reverse endocrine resistance in patients with a history of previous durable response to ET itself.^[@bibr40-1758835919833864]^

Ultimately, additional determinants of choice of the best treatment strategy should be considered, such as pharmacoeconomic issues, regulatory drug availability, toxicity issues, patient compliance, and attitude to long-term treatment adherence.

Conclusion {#section16-1758835919833864}
==========

Our real-life experience confirms that F500 can be safely offered to most women with HR+/HER2− MBC, producing clinical activity both in patients treated upon PD and in those receiving the drug as a maintenance strategy. In addition, the search for potential predictive or prognostic factors showed that neither tumor-related nor patient-related variables significantly affected the probability of response, thus suggesting a good performance of the drug in the various clinical situations. The statistically significant correlation found between an earlier administration of the drug and a better clinical outcome adds information for daily decision-making, aiming for a personalized approach to treatment selection.

**Funding:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest statement:** The authors declare that there is no conflict of interest.
